Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Evaluation of Interferon-gamma Responses to HCMV Infection in HIV Positive Individuals

This study has been completed.
Information provided by (Responsible Party):
Jennifer Hoy, The Alfred Identifier:
First received: September 13, 2005
Last updated: January 19, 2012
Last verified: January 2012

The study is designed to evaluate interferon responses to CMV in HIV positive individuals and a component will look at interferon responses to CMV in HIV positive individuals over time after commencement of antiretroviral therapy. We will also look at the correlation between CD4 T cell numbers and HLA type with the interferon response.

HIV Infection
CMV Infection

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Evaluation of Interferon-gamma Responses to HCMV Infection in HIV Positive Individuals

Resource links provided by NLM:

Further study details as provided by The Alfred:

Biospecimen Retention:   Samples With DNA

Plasma, and DNA

Enrollment: 20
Study Start Date: December 2004
Study Completion Date: December 2009

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

HIV infected patients with past CMV infection initiating antiretroviral therapy


Inclusion Criteria:

  1. HIV positive with history of documented HCV infection
  2. Over 18 years old
  3. HIV positive
  4. Antiretroviral naive, starting on antiretroviral therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00168259

Australia, Victoria
Alfred Hospital
Melbourne, Victoria, Australia, 3004
Sponsors and Collaborators
The Alfred
Principal Investigator: Sharon Lewin, Professor The Alfred
  More Information

No publications provided

Responsible Party: Jennifer Hoy, Professor Jennifer Hoy, The Alfred Identifier: NCT00168259     History of Changes
Other Study ID Numbers: 185/04
Study First Received: September 13, 2005
Last Updated: January 19, 2012
Health Authority: Australia: National Health and Medical Research Council

Keywords provided by The Alfred:
Treatment Naive

Additional relevant MeSH terms:
Communicable Diseases
Anti-Infective Agents
Antiviral Agents
Pharmacologic Actions
Therapeutic Uses processed this record on February 27, 2015